Efficiency and Safety of Collagen Biomaterial in Treatment of Diabetic Foot Syndrome


Journal of Pharmaceutical Sciences and Research. Vol. 9(5), 2017, 732-736

To improve the results of treatment of patients with diabetic foot syndrome, including the use of collagen biomaterial. We have made a multicentre study with the participation of 71 patients with diabetic foot syndrome of different severity levels. The patients were randomized into two homogeneous groups: 1) group of standard therapy (n=35); and 2) group with additional administration of collagen biomaterial (Collost/Salvecoll) (n=36). The dynamic assessment of patients was performed when including into the study and on the 7th, 14th and 28th day of treatment.